Journal
TRENDS IN IMMUNOLOGY
Volume 34, Issue 11, Pages 548-555Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.it.2013.07.004
Keywords
-
Categories
Funding
- Cancer Research Institute
- National Health and Medical Research Council of Australia (NH&MRC) Program Grant and Australia Fellowship
- NH&MRC CDF1 Fellowship
Ask authors/readers for more resources
Interleukin (IL)-12 and IL-23 share the IL-12p40 molecule. IL-12 promotes T helper (Th)1 immunity and IL-23 promotes Th17 immunity, and it has recently become apparent that the balance between IL-12 and IL-23 is important in carcinogenesis. A series of studies demonstrated that, where tumor initiation, growth, and metastasis are concerned, IL-12 may act independently of interferon (IFN)-gamma, and IL-23 independently of IL-17A. This review explores the activity of IL-23 in carcinogenesis. In the context of the tumor-inhibitory effects of IL-12, and tumor-promoting effects of IL-23, we discuss the use of anti-IL-12p/23 monoclonal antibodies (mAbs) in autoimmune inflammatory disorders and the alternative specific neutralization of IL-23.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available